Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFP-10917 + Venetoclax in R/R AML
NCT06382168Phase 2Recruiting
- Sponsor
- Delta-Fly Pharma, Inc.
- Start
- Jun 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of radgocitabine in acute myeloid leukemia (AML), sponsored by Delta-Fly Pharma, Inc.. Started Jun 2024; status: recruiting.
02
Drugs
radgocitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06382168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06382168.